Literature DB >> 35796921

Variant Type X91+ Chronic Granulomatous Disease: Clinical and Molecular Characterization in a Chinese Cohort.

Bijun Sun1, Zeyu Zhu1,2, Xiaoying Hui1, Jinqiao Sun1, Wenjie Wang1, Wenjing Ying1, Qinhua Zhou1, Haili Yao1, Jia Hou3,4, Xiaochuan Wang5,6.   

Abstract

PURPOSE: We aimed to report the clinical and immunological characteristics of variant type X91+ chronic granulomatous disease (CGD) in a Chinese cohort.
METHODS: The clinical manifestations and immunological phenotypes of patients with X91+ CGD were collected. A dihydrorhodamine (DHR) analysis was performed to evaluate neutrophil function. Gp91phox protein expression was determined using extracellular staining with the monoclonal antibody (mAb) 7D5 and flow cytometry.
RESULTS: Patients with X91+ CGD accounted for 8% (7/85) of all patients with CGD. The median age of onset in the seven patients with X91+ CGD was 4 months. Six patients received the BCG vaccine, and 50% (3/6) had probable BCG infections. Mycobacterium tuberculosis infection was prominent. The most common sites of infection were the lung (6/7), lymph nodes (5/7), and soft tissue (3/7). Two patients experienced recurrent oral ulcers. The stimulation index (SI) of the patients with X91+ CGD ranged widely from 1.9 to 67.3. The difference in the SI among the three groups of patients (X91+ CGD, X91- CGD, and X910 CGD) was statistically significant (P = 0.0071). The three groups showed no significant differences in onset age, diagnosis age, or severe infection frequency. CYBB mutations associated with X91+ CGD were commonly located in the second transmembrane or intracellular regions. Three novel X91+ CGD-related mutations (c.1462-2 A > T, c.1243C > T, and c.925G > A) were identified.
CONCLUSIONS: Variant type X91+ CGD may result in varied clinical manifestations. Moreover, the laboratory findings might indicate a moderate neutrophil SI. We should deepen our understanding of variant X91+ CGD to prevent missed diagnoses.
© 2022. The Author(s).

Entities:  

Keywords:  Chronic granulomatous disease; NADPH oxidase; Neutrophil respiratory burst; Stimulation index; gp91phox

Year:  2022        PMID: 35796921     DOI: 10.1007/s10875-022-01324-3

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  49 in total

Review 1.  Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease.

Authors:  D Roos; M de Boer; F Kuribayashi; C Meischl; R S Weening; A W Segal; A Ahlin; K Nemet; J P Hossle; E Bernatowska-Matuszkiewicz; H Middleton-Price
Journal:  Blood       Date:  1996-03-01       Impact factor: 22.113

2.  Four novel mutations in the gene encoding gp91-phox of human NADPH oxidase: consequences for oxidase assembly.

Authors:  J H Leusen; C Meischl; M H Eppink; P M Hilarius; M de Boer; R S Weening; A Ahlin; L Sanders; D Goldblatt; H Skopczynska; E Bernatowska; J Palmblad; A J Verhoeven; W J van Berkel; D Roos
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

3.  A Cohort of 169 Chronic Granulomatous Disease Patients Exposed to BCG Vaccination: a Retrospective Study from a Single Center in Shanghai, China (2004-2017).

Authors:  Qinhua Zhou; Xiaoying Hui; Wenjing Ying; Jia Hou; Wenjie Wang; Danru Liu; Ying Wang; Yeheng Yu; Jingyi Wang; Jinqiao Sun; Qian Zhang; Xiaochuan Wang
Journal:  J Clin Immunol       Date:  2018-03-20       Impact factor: 8.317

4.  Chronic granulomatous disease (CGD) and complete myeloperoxidase deficiency both yield strongly reduced dihydrorhodamine 123 test signals but can be easily discerned in routine testing for CGD.

Authors:  Lysann Mauch; Andreas Lun; Maurice R G O'Gorman; John S Harris; Ilka Schulze; Arturo Zychlinsky; Tobias Fuchs; Uta Oelschlägel; Sebastian Brenner; Dolphe Kutter; Angela Rösen-Wolff; Joachim Roesler
Journal:  Clin Chem       Date:  2007-03-23       Impact factor: 8.327

5.  Statistical and mutational analysis of chronic granulomatous disease in Japan with special reference to gp91-phox and p22-phox deficiency.

Authors:  F Ishibashi; H Nunoi; F Endo; I Matsuda; S Kanegasaki
Journal:  Hum Genet       Date:  2000-05       Impact factor: 4.132

6.  Functional analysis of two-amino acid substitutions in gp91 phox in a patient with X-linked flavocytochrome b558-positive chronic granulomatous disease by means of transgenic PLB-985 cells.

Authors:  Clara Bionda; Xing Jun Li; Robin van Bruggen; Michel Eppink; Dirk Roos; Françoise Morel; Marie-José Stasia
Journal:  Hum Genet       Date:  2004-08-24       Impact factor: 4.132

7.  Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes.

Authors:  S J Vowells; S Sekhsaria; H L Malech; M Shalit; T A Fleisher
Journal:  J Immunol Methods       Date:  1995-01-13       Impact factor: 2.303

8.  First report of clinical, functional, and molecular investigation of chronic granulomatous disease in nine Jordanian families.

Authors:  Faris G Bakri; Cécile Martel; Najwa Khuri-Bulos; Azmi Mahafzah; Mohammad S El-Khateeb; Adel M Al-Wahadneh; Wail A Hayajneh; Hanan A Hamamy; Elisabeth Maquet; Michelle Molin; Marie José Stasia
Journal:  J Clin Immunol       Date:  2008-09-05       Impact factor: 8.317

9.  Capture-based high-coverage NGS: a powerful tool to uncover a wide spectrum of mutation types.

Authors:  Jing Wang; Hui Yu; Victor Wei Zhang; Xia Tian; Yanming Feng; Guoli Wang; Elizabeth Gorman; Hao Wang; Richard E Lutz; Eric S Schmitt; Sandra Peacock; Lee-Jun Wong
Journal:  Genet Med       Date:  2015-09-24       Impact factor: 8.822

Review 10.  Hematologically important mutations: X-linked chronic granulomatous disease (fourth update).

Authors:  Dirk Roos; Karin van Leeuwen; Amy P Hsu; Debra Long Priel; Amber Begtrup; Rhonda Brandon; Marie José Stasia; Faris Ghalib Bakri; Nezihe Köker; M Yavuz Köker; Manisha Madkaika; Martin de Boer; Maria Bravo Garcia-Morato; Juan Luis Valdivieso Shephard; Joachim Roesler; Hirokazu Kanegane; Toshinao Kawai; Gigliola Di Matteo; Mohammad Shahrooei; Jacinta Bustamante; Amit Rawat; Pandiarajan Vignesh; Esmaeil Mortaz; Abbas Fayezi; Deniz Cagdas; Ilhan Tezcan; Maleewan Kitcharoensakkul; Mary C Dinauer; Isabelle Meyts; Baruch Wolach; Antonio Condino-Neto; Christa S Zerbe; Steven M Holland; Harry L Malech; John I Gallin; Douglas B Kuhns
Journal:  Blood Cells Mol Dis       Date:  2021-06-02       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.